Benitec Biopharma, Inc. (BNTC)
12.64
-0.08
(-0.63%)
USD |
NASDAQ |
Sep 09, 10:53
Benitec Biopharma Enterprise Value : 253.16M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 253.16M |
| September 04, 2026 | 251.61M |
| September 03, 2026 | 243.37M |
| September 02, 2026 | 258.48M |
| September 01, 2026 | 238.90M |
| August 31, 2026 | 234.09M |
| August 28, 2026 | 244.40M |
| August 27, 2026 | 251.27M |
| August 26, 2026 | 258.48M |
| August 25, 2026 | 263.29M |
| August 24, 2026 | 252.64M |
| August 21, 2026 | 279.10M |
| August 20, 2026 | 262.95M |
| August 19, 2026 | 275.66M |
| August 18, 2026 | 258.48M |
| August 17, 2026 | 265.01M |
| August 14, 2026 | 247.49M |
| August 13, 2026 | 247.49M |
| August 12, 2026 | 239.93M |
| August 11, 2026 | 279.10M |
| August 10, 2026 | 289.40M |
| August 07, 2026 | 284.25M |
| August 06, 2026 | 267.07M |
| August 05, 2026 | 251.96M |
| August 04, 2026 | 246.12M |
| Date | Value |
|---|---|
| August 03, 2026 | 233.41M |
| July 31, 2026 | 218.29M |
| July 30, 2026 | 223.44M |
| July 29, 2026 | 229.97M |
| July 28, 2026 | 224.47M |
| July 27, 2026 | 213.82M |
| July 24, 2026 | 210.04M |
| July 23, 2026 | 209.01M |
| July 22, 2026 | 209.01M |
| July 21, 2026 | 224.47M |
| July 20, 2026 | 227.22M |
| July 17, 2026 | 255.05M |
| July 16, 2026 | 250.93M |
| July 15, 2026 | 263.29M |
| July 14, 2026 | 261.92M |
| July 13, 2026 | 262.26M |
| July 10, 2026 | 277.04M |
| July 09, 2026 | 279.10M |
| July 08, 2026 | 279.10M |
| July 07, 2026 | 277.72M |
| July 06, 2026 | 269.48M |
| July 02, 2026 | 270.16M |
| July 01, 2026 | 251.96M |
| June 30, 2026 | 275.66M |
| June 29, 2026 | 252.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.94M |
| Total Expenses (Quarterly) | 11.94M |
| EPS Diluted (Quarterly) | -0.2417 |
| Earnings Yield | -7.35% |
| Normalized Earnings Yield | -7.347 |